The House Committee on Energy and Commerce Jan. 27 released a draft version of a massive bill that seeks to streamline the pathways of innovation in medicine.
The Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion for Jakavi (ruxolitinib) for the treatment of adult patients with polycythemia vera who are resistant to or intolerant of hydroxyurea. If approved in the EU, ruxolitinib could provide the first targeted treatment option for these patients.
Ventana Medical Systems Inc., a member of the Roche Group, announced its FDA submission for premarket approval of the VENTANA ALK (D5F3) CDx Assay.
Palmetto GBA, a national contractor that administers Medicare benefits, issued a positive coverage policy through the MolDX Program for the Decipher prostate cancer classifier developed by GenomeDx Biosciences.
PICADOR acquired world rights to a debut novel by Paul Goldberg, editor and publisher of The Cancer Letter. Set in Moscow in late February and early March of 1953, the novel is only in part about medicine. It's expected to be published in early 2016.
ROYAL PHILIPS will analyze pathology samples using advanced image analysis algorithms from Indica Labs Inc. as part of its Digital Pathology Solutions offerings.
THE MEDICAL UNIVERSITY OF SOUTH CAROLINA Hollings Cancer Center's Mount Pleasant location installed TrueBeam imaging capabilities for patients, as well as several types of external beam radiation therapy.
JOHNATHAN LANCASTER joined Myriad Genetics as vice president of medical affairs for oncology in Myriad Genetic Laboratories, effective Feb. 9.
WUXI PHARMATECH (Cayman) Inc. acquired NextCODE Health for $65 million in cash, with plans to merge NextCODE and WuXi's Genome Center into a new company, named WuXi NextCODE Genomics.
CITY OF HOPE and Trovagene Inc. entered into a clinical collaboration to conduct studies on detecting and monitoring EGFR mutations in lung cancer patients using Trovagene's Precision Cancer Monitoring platform.
